Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 181

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis

Garren, Hideki, Robinson, William H., Krasulová, Eva, Havrdová, Eva, Nadj, Congor, Selmaj, Krzysztof, Losy, Jacek, Nadj, Ilinka, Radue, Ernst‐Wilhelm, Kidd, Brian A., Gianettoni, Jill, Tersini, Karen, Utz, Paul J., Valone, Frank, Steinman, Lawrence, BHT‐3009 Study Group · 2008 · Annals of Neurology

Abstract

Objective: To evaluate the efficacy and safety of BHT‐3009 in relapsing‐remitting multiple sclerosis (MS) and to confirm that BHT‐3009 causes immune tolerance. Methods: BHT‐3009 is a tolerizing DNA vaccine for MS, encoding full‐length human myelin basic protein. Relapsing‐remitting MS patients were randomized 1:1:1 into three groups: placebo, 0.5mg BHT‐3009, or 1.5mg BHT‐3009, given intramuscularly at weeks 0, 2, 4, and every 4 weeks thereafter until week 44. The primary end point was the 4‐week rate of occurrence of new gadolinium‐enhancing lesions on brain magnetic resonance images from weeks 28 to 48. Protein microarrays were used to measure levels of anti‐myelin autoantibodies. Results: Compared with placebo, in the 267 patient analysis population the median 4‐week rate of new enhancing lesions during weeks 28 to 48 was 50% lower with 0.5mg BHT‐3009 (p = 0.07) and during weeks 8 to 48 was 61% lower with 0.5mg BHT‐3009 (p = 0.05). The mean volume of enhancing lesions at week 48 was 51% lower on 0.5mg BHT‐3009 compared with placebo (p = 0.02). No significant improvement in magnetic resonance imaging lesion parameters was observed with 1.5mg BHT‐3009. Dramatic reductions in 23 myelin‐specific autoantibodies in the 0.5mg BHT‐3009 arm were observed, but not with placebo or 1.5mg BHT‐3009. Conclusions: In relapsing‐remitting MS patients, treatment with the lower dose (0.5mg) of BHT‐3009 for 44 weeks nearly attained the primary end point for reduction of the rate of new enhancing magnetic resonance imaging lesions (p = 0.07) and achieved several secondary end points including a reduction of the rate of enhancing magnetic resonance imaging lesions from weeks 8 to 48 (p = 0.05). Immunological data in a preselected subgroup of patients also indicated that treatment with 0.5mg induced antigen‐specific immune tolerance. The greater dose was ineffective. Ann Neurol 2008;63:611–620

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.21370

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 181

Metadata

Authors
Garren, H., Robinson, W. H., Krasulová, E., Havrdová, E., Nadj, C., Selmaj, K., Losy, J., Nadj, I., Radue, E., Kidd, B. A., Gianettoni, J., Tersini, K., Utz, P. J., Valone, F., Steinman, L., & BHT‐3009 Study Group
Venue
Annals of Neurology
Publisher
Wiley
Published
2008-05
Volume
63
Issue
5
Pages
611-620
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W2122529630
Cited by
181
References
2
FWCI
9.69
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. https://app.cochat.ai/papers/10.1002/ana.21370
The paper
Garren, H., Robinson, W. H., Krasulová, E., Havrdová, E., Nadj, C., Selmaj, K., Losy, J., Nadj, I., Radue, E., Kidd, B. A., Gianettoni, J., Tersini, K., Utz, P. J., Valone, F., Steinman, L., & BHT‐3009 Study Group. (2008). Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Annals of Neurology. https://doi.org/10.1002/ana.21370

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.